Biogenvs.United Therapeutics
BIIB vs UTHR · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Biogen is about 1.3× larger than United Therapeutics by market cap; United Therapeutics trades at the lower P/E (18.0 vs 21.3).
Side by side
| BIIB | UTHR | |
|---|---|---|
| Market cap | $29.3B | $23.2B |
| Price | $199.15 | $547.06 |
| Today | +0.1% | −1.0% |
| Return YTD | +13.2% | +12.3% |
| Return 1Y | +47.2% | +82.3% |
| P/E | 21.3 | 18.0 |
| P/S | 2.9 | 7.3 |
| P/B | 1.6 | 3.9 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
BiogenBIIB
American biotech company focused on neurological diseases — including Alzheimer's (Leqembi, with Eisai) and MS.
Full BIIB profile →United TherapeuticsUTHR
Biopharma in pulmonary hypertension and organ manufacturing (xenotransplantation).
Full UTHR profile →More comparisons in Biotech & innovation
See where BIIB and UTHR sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →